Hepatitis C Virus NS5A Inhibitor [EPC]

48073 reported adverse events

Drugs of this class: LEDIPASVIR AND SOFOSBUVIR VELPATASVIR AND SOFOSBUVIR ELBASVIR AND GRAZOPREVIR GLECAPREVIR AND PIBRENTASVIR SOFOSBUVIR, VELPATASVIR, AND VOXILAPREVIR

These side effects are most commonly reported by patients taking drugs of the Hepatitis C Virus NS5A Inhibitor [EPC] class:

# Side effect Count
0 FATIGUE 10471
1 HEADACHE 9015
2 NAUSEA 4215
3 DIARRHOEA 2398
4 DRUG INEFFECTIVE 2021
5 INSOMNIA 1890
6 HEPATITIS C 1565
7 VOMITING 1305
8 PRURITUS 1299
9 DIZZINESS 1089
See all common reactions for Hepatitis C Virus NS5A Inhibitor [EPC]

Drugs of the Hepatitis C Virus NS5A Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 HEPATITIS C VIRUS TEST POSITIVE 189 0.3214
1 HEPATITIS C RNA POSITIVE 39 0.2281
2 GENOTYPE DRUG RESISTANCE TEST POSITIVE 202 0.1965
3 HEPATIC CANCER RECURRENT 51 0.1796
4 HEPATITIS C 1565 0.1295
5 HEPATOCELLULAR CARCINOMA 574 0.0754
6 OESOPHAGEAL VARICES HAEMORRHAGE 86 0.0396
7 LIVER TRANSPLANT 94 0.0258
8 HEPATIC PAIN 108 0.0253
9 VIRAL LOAD INCREASED 96 0.0247
See all enriched reactions for Hepatitis C Virus NS5A Inhibitor [EPC]